Browsing Tag
CagriSema
4 posts
Novo Nordisk’s Wegovy pill reaches DKK5.4bn sales as DKK8.7bn impairments hit profit
Novo Nordisk reported stronger-than-expected third-quarter results and raised its annual sales and operating profit forecasts after the Wegovy pill gained commercial momentum. However, substantial impairment charges and continuing competition in obesity treatment reveal why the company's recovery remains financially complicated.
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.
Novo Nordisk’s CagriSema demonstrates superior weight loss results in REDEFINE 1 trial
Novo Nordisk A/S has unveiled significant findings from its REDEFINE 1 trial, marking a major advancement in the…